Patient Assistance Program Administration

Access to optimal cancer treatments is critical to improving the lives of cancer survivors in every country around the world. The Max Foundation is committed to helping people living with cancer navigate their local healthcare systems to facilitate access to treatment and support.

There are various paths to treatment access, such as through government programs, clinical trials, or through Patient Assistance Programs (PAPs), also known as drug access programs.

Since 2001, The Max Foundation has partnered in the administration of Novartis’ Glivec International Patient Assistance Program (GIPAP), an unparalleled drug access program for Glivec. The Max Foundation now supports the administration of other Novartis Oncology Access programs in countries such as Malaysia, India and Thailand.

In addition to helping guide patients and their doctors through the PAP enrollment process, The Max Foundation provides program beneficiaries including their family members, with free services of emotional support, informational referrals and advocacy.

For more information, please click on the links provided below:

GIPAP | What is GIPAP | What is Glivec | GIPAP Qualification Requirements | Physician Instructions | GIPAP FAQ | Contact GIPAP